Biotechnology News and Research

RSS

First patient dosed in ADXS-HPV Phase 1/2 study for HPV-associated head and neck cancer

Advaxis, Inc., a leader in developing the next generation of cancer immunotherapies, announced that the first patient has been dosed in a Phase 1/2 "window of opportunity" study being conducted by the Icahn School of Medicine at Mount Sinai. Patients diagnosed with HPV-associated head and neck cancer will receive ADXS-HPV immunotherapy during the "window" of time between initial diagnosis and minimally invasive transoral robotic surgery to remove their tumors.

21 Jan 2014

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

Alexion Pharmaceuticals today announced that the U.S. Food and Drug Administration has granted an orphan drug designation to Soliris (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of delayed graft function in renal transplant patients.

21 Jan 2014

PLSG reaches significant landmark in direct investments into life sciences companies

Pittsburgh Life Sciences Greenhouse, the region's only pure life sciences investment firm, and managing member of the PLSG Accelerator Fund, announced today it has made a $65,000 investment into Cohera Medical, Inc. which launches the organization into a $20 million milestone in total investments since the company's inception in 2001.

21 Jan 2014

Affymetrix gets FDA clearance to market CytoScan Dx Assay

Affymetrix, Inc. today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration to market its CytoScan Dx Assay. This assay is intended for the postnatal detection of DNA copy number variants in patients referred for chromosomal testing. CytoScan Dx Assay is designed to help physicians diagnose children's developmental and intellectual disabilities more comprehensively by enabling a high-resolution genome-wide analysis of genetic aberrations. High resolution analysis can reveal small aberrations not readily seen using traditional techniques.

21 Jan 2014

Synthelis secures initial funding to accelerate commercial development of membrane proteins

Synthelis, a company specializing in the production and characterization of therapeutic targets and antigens, announces today that it has secured initial backing of EUR 610,000 from a group of French investors comprising Rhone-Alpes Creation, Alpes Developpement Durable Investissement (A2D-Invest), Sud Rhone-Alpes Capital, Viaduc and the Savoy and Grenoble Business Angels networks.

21 Jan 2014

RBCC's partner Nano3D Biosciences develops new 3D bioprinting system

Rainbow Coral Corp. is well-positioned to capitalize on the revolution in medicine being spurred on by 3D printing technology thanks to the innovative BiO Assay, a new 3D bioprinting system developed by RBCC's joint venture partner, Nano3D Biosciences (n3D).

20 Jan 2014

Researchers develop 3 hypoallergenic variants of Pru p 3 protein

A research conducted by the Centre for Plant Biotechnology and Genomics (UPM-INIA) and led by Araceli Díaz Perales has studied the allergy to peach, the most common food allergy, and the Pru p 3 protein. As a result of this research work, they have developed three hypoallergenic variants of this protein. All can be good candidates for the usage of specific immunotherapy for peach allergy and also can be used as a vaccine.

20 Jan 2014

Scientists uncover how microbiota metabolise complex dietary carbohydrates found in fruits, vegetables

We are all aware of the health benefits of "dietary fibre". But what is dietary fibre and how do we metabolise it?

20 Jan 2014

Queen's University Belfast scientists receive international recognition for research on microneedles

Scientists from Queen's University Belfast, whose research into microneedles is taking the pain out of injections, have received international recognition from one of the world's leading pharmaceutical science journals.

20 Jan 2014

BioTime subsidiary releases version 1.5 of LifeMap Discovery

LifeMap Sciences, Inc., a subsidiary of BioTime, Inc., announced today the release of LifeMap Discovery version 1.5. LifeMap Discovery is a state-of-the-art roadmap of embryonic development and stem cell biology.

18 Jan 2014

$Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL$

Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL

Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval of ADCETRIS (brentuximab vedotin) from the Japanese Ministry of Health, Labour and Welfare for the treatment of patients with CD30-positive relapsed or refractory Hodgkin lymphoma and anaplastic large cell lymphoma.

18 Jan 2014

Biothera enhances innate immune responses to Imprime PGG drug candidate

Biothera has enhanced innate immune responses to its cancer immunotherapy drug candidate Imprime PGG in subjects regardless of biomarker status, demonstrating the opportunity to treat a larger patient population. The in vitro research will be presented today at the Cambridge Healthtech Institute's Antibody-Drug Conjugates/Engineering Targeted Therapeutics conference in Palm Springs, CA.

16 Jan 2014

Crozer-Keystone Health System wins 2013 Foster G. McGaw Prize for Excellence in Community Service

In honor of its broad-based efforts to improve the lives of the most vulnerable members of its community, Crozer-Keystone Health System in Delaware County, Pa. is the recipient of the 2013 Foster G. McGaw Prize for Excellence in Community Service, one of the most esteemed community service honors in healthcare.

From Baxter International Inc. 16 Jan 2014

Transgenomic, Horizon Discovery collaborate to develop improved genetic diagnostic tests with state of art controls

Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, and Horizon Discovery Ltd. (Horizon), a leading provider of research tools to support translational genomics and the development of personalized medicines, today announced they have entered into a collaboration agreement to develop improved genetic diagnostic tests incorporating state of the art controls.

16 Jan 2014

Atlas develops ultra-rapid point-of-care tests for a range of infectious diseases

Atlas Genetics Ltd, the diagnostic company developing ultra-rapid point-of-care (POC) tests for a range of infectious diseases, today announces that it has completed development of the Atlas io™ Reader, a POC device that can deliver laboratory quality results for molecular assays in under thirty minutes.

16 Jan 2014

Scientists develop new nasal vaccine that proves effective against whooping cough

Scientists involved in the EU-funded project ChildInnovac are about to publish in the online journal Plos One the results of their first clinical trial of a new nasal vaccine.

16 Jan 2014

Researchers develop "smart" hydrogel that can deliver medicine on demand

Researchers at the University of Delaware have developed a "smart" hydrogel that can deliver medicine on demand, in response to mechanical force.

16 Jan 2014

FAMPYRA now available in Ireland for symptomatic treatment of walking impairment in MS patients

Biogen Idec today announced that FAMPYRA (prolonged-release fampridine tablets) has been made available in Ireland for the symptomatic treatment of walking impairment in adults with Multiple Sclerosis. FAMPYRA is a prescription drug and is licensed for use in all types of the disease, including the progressive forms. FAMPYRA is available by way of retail pharmacy on a private payment basis.

15 Jan 2014

TaiGen, R-Pharm sign exclusive agreement to develop and commercialize nemonoxacin

TaiGen Biotechnology Company, Limited today announced that they have signed an exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn) in the Russian Federation, Turkey and other members of the Commonwealth Independent States.

15 Jan 2014

Research paper highlights the role of T-cells in HIV

Ryan Zurakowski, assistant professor of electrical and computer engineering at the University of Delaware, is co-author of a paper appearing in Nature Medicine on Jan. 12 highlighting the role of T-cells in HIV.

15 Jan 2014

Biotechnology News and Research

First patient dosed in ADXS-HPV Phase 1/2 study for HPV-associated head and neck cancer

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

PLSG reaches significant landmark in direct investments into life sciences companies

Affymetrix gets FDA clearance to market CytoScan Dx Assay

Synthelis secures initial funding to accelerate commercial development of membrane proteins

RBCC's partner Nano3D Biosciences develops new 3D bioprinting system

Researchers develop 3 hypoallergenic variants of Pru p 3 protein

Scientists uncover how microbiota metabolise complex dietary carbohydrates found in fruits, vegetables

Queen's University Belfast scientists receive international recognition for research on microneedles

BioTime subsidiary releases version 1.5 of LifeMap Discovery

Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL

Biothera enhances innate immune responses to Imprime PGG drug candidate

Crozer-Keystone Health System wins 2013 Foster G. McGaw Prize for Excellence in Community Service

Transgenomic, Horizon Discovery collaborate to develop improved genetic diagnostic tests with state of art controls

Atlas develops ultra-rapid point-of-care tests for a range of infectious diseases

Scientists develop new nasal vaccine that proves effective against whooping cough

Researchers develop "smart" hydrogel that can deliver medicine on demand

FAMPYRA now available in Ireland for symptomatic treatment of walking impairment in MS patients

TaiGen, R-Pharm sign exclusive agreement to develop and commercialize nemonoxacin

Research paper highlights the role of T-cells in HIV

Biotechnology eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News